Clinical Resources

Featured Research, Dosing Tables by weight,
and other technical materials

Expanding access to care beyond the hospital.

Featured Research

A New Standard for Pancreatitis Care

A landmark study published in the Journal of Veterinary Internal Medicine (JVIM) proves that the RxActuator Mini-Infuser™ enables a highly successful outpatient protocol for managing canine pancreatitis.

By delivering continuous, low-dose subcutaneous analgesia, the device maintains a steady-state therapeutic level that allows stable patients to recover in the comfort of home rather than a high-stress ICU. This shift from prolonged hospitalization to evidence-based outpatient care ensures gold-standard pain management while significantly optimizing clinic resources and lowering client costs by 62-74%.

Clinical Outcomes & Efficacy

  • 89.5% Outpatient Success: 17 of 19 dogs were successfully managed as outpatients, avoiding the need for multi-day inpatient stays.

  • Complete Pain Resolution: Median pain scores (GCMPS) plummeted from a 7.5 to 0 within the first 48 hours of treatment.

  • Rapid Symptom Reduction: Patients saw a 50% decrease in clinical severity scores (MCAI) during the 48-hour infusion period.

  • Zero "Peak & Valley" Risk: Constant-rate infusion (CRI) maintains consistent drug levels, eliminating the toxic spikes and sub-therapeutic dips common with bolus dosing.

Financial & Operational Impact

  • Maximize Cage Throughput: Transitioning stable patients home on Day 1 frees up critical ICU space for higher-margin surgical or emergency cases.

  • Reduced Technician Labor: The silent, water-activated pump eliminates "nuisance alarms" and the need for constant IV line monitoring, allowing staff to focus on high-priority tasks.

  • Increased Client Compliance: By reducing the cost barrier of traditional $3,000+ hospitalization, more pet owners can opt for advanced treatment, improving overall practice revenue.

  • Optimized Practice ROI: Recapture "Device + Oversight" revenue while eliminating the low-margin overhead of long-term boarding and maintenance.

"Outpatient management of suspected pancreatitis cases can be safe."

Clinically Validated Results

Our technology isn't just innovative; it’s proven. Pharmacokinetic studies conducted at leading institutions like North Carolina State University (NCSU) College of Veterinary Medicine have verified our clinical results:

  • Constant Concentration: Eliminates the "peaks and valleys" associated with manual injections.
  • Enhanced Efficacy: Studies showed that the Mini-Infuser® can maintain effective blood levels of medications like Hydromorphone and Ceftazidime over 48 hours.
  • Reduced Dosage: In some cases, constant infusion allowed for lower overall drug dosages compared to traditional IV methods while maintaining therapeutic levels.
 Learn More

Dosing Tables by Weight

Ketamine at 3 micrograms/kg/minute See Table
Ketamine at 4 micrograms/kg/minute See Table 
Hydromorphone at 0.01 mg/kg/hr See Table


Chronic Pain and Ketamine

Maximize your clinic's impact on canine chronic pain with the Mini-Infuser drug delivery pump, providing precise ketamine infusions that target NMDA receptors to reverse central sensitization. This advanced system offers a transformative, multimodal solution for treating maladaptive pain and improving long-term quality of life for veterinary patients.

Dr. Lindsey Fry, DVM, cVMA, CCRP, CVPP A Novel Approach with a Familiar Tool—Part 1 Review of Ketamine and Chronic Pain Read Paper
Dr. Lindsey Fry, DVM, cVMA, CCRP, CVPP A Novel Approach with a Familiar Tool—Part 2 Clinical Application and Case Studies Read Paper
Dr. Lindsey Fry, DVM, cVMA, CCRP, CVPP Ketamine and Maladaptive Pain Watch Video

 

Acute Pain and Hydromorphone

The RxActuator Mini-Infuser® provides a solution for outpatient canine pain management by delivering a consistent 48-hour subcutaneous infusion of hydromorphone at therapeutic plasma levels. This wearable drug delivery pump ensures reliable, long-term analgesia for dogs, overcoming the limitations of traditional bolus dosing for chronic and moderate pain.

James S. Gaynor, DVM, MS, DACVAA, DAIPM The Perfect Pump: Wearable Pumps for Pain Control Read Paper
K. Messenger ; H. Enomoto ; H. Knych ; M. Papich Pharmacokinetics of Hydromorphone in Dogs after Intravenous Bolus and Delivered Subcutaneously with the RxActuator Mini-Infuser® Infusion Pump Read Paper
Kristen Messenger, Hiroko Enomoto, Melanie Madsen,
Heather Knych, and Mark Papich		 Pharmacokinetics of Hydromorphone in
Dogs after Intravenous Bolus and Delivered Subcutaneously with the
RxActuator Mini-Infuser® Infusion pump		 View Presentation

 

Anti Microbial Infusion with Ceftazidime

The RxActuator Mini-Infuser® ensures optimal therapeutic outcomes for time-dependent antimicrobials by delivering a continuous 48-hour subcutaneous infusion of ceftazidime in dogs, eliminating frequent, stressful injections while maintaining steady-state plasma concentrations essential for treating resistant canine bacterial infections.

Mark G. Papich DVM, MS, DACVCP Melanie Madsen DVM Kristen Messenger DVM, PhD, DACVAA, DACVCP Hiroko Enomoto DVM Ceftazidime pharmacokinetics in dogs after intravenous injection and delivered with the RxActuator Mini-Infuser infusion pump Read Paper